157 related articles for article (PubMed ID: 37468447)
1. Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.
Fernandes M; Paget S; Kherrouche Z; Truong MJ; Vinchent A; Meneboo JP; Sebda S; Werkmeister E; Descarpentries C; Figeac M; Cortot AB; Tulasne D
FEBS Lett; 2023 Sep; 597(18):2301-2315. PubMed ID: 37468447
[TBL] [Abstract][Full Text] [Related]
2. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paik PK; Drilon A; Fan PD; Yu H; Rekhtman N; Ginsberg MS; Borsu L; Schultz N; Berger MF; Rudin CM; Ladanyi M
Cancer Discov; 2015 Aug; 5(8):842-9. PubMed ID: 25971939
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of
Yu Y; Zhang Q; Zhang J; Lu S
J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
[TBL] [Abstract][Full Text] [Related]
4. [Expert Consensus on Targeted Therapy of NSCLC with MET Exon 14
Skipping Mutation].
Editorial Office of Chinese Journal of Lung Cancer
Zhongguo Fei Ai Za Zhi; 2023 Jun; 26(6):416-428. PubMed ID: 37488079
[TBL] [Abstract][Full Text] [Related]
5. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
6. Management of Non-small Cell Lung Cancer Patients with MET Exon 14 Skipping Mutations.
Huang C; Zou Q; Liu H; Qiu B; Li Q; Lin Y; Liang Y
Curr Treat Options Oncol; 2020 Apr; 21(4):33. PubMed ID: 32306194
[TBL] [Abstract][Full Text] [Related]
7. Clinical response to crizotinib and emergence of resistance in lung adenocarcinoma harboring a MET c-Cbl binding site mutation.
Wiesweg M; Herold T; Metzenmacher M; Eberhardt WE; Reis H; Darwiche K; Aigner C; Stuschke M; Herrmann K; Nensa F; Schildhaus HU; Schuler M
Lung Cancer; 2020 Jan; 139():165-168. PubMed ID: 31809977
[TBL] [Abstract][Full Text] [Related]
8. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
9. [MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].
Yin L; Lu Y
Zhongguo Fei Ai Za Zhi; 2018 Jul; 21(7):553-559. PubMed ID: 30037377
[TBL] [Abstract][Full Text] [Related]
10. Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping.
Heist RS; Sequist LV; Borger D; Gainor JF; Arellano RS; Le LP; Dias-Santagata D; Clark JW; Engelman JA; Shaw AT; Iafrate AJ
J Thorac Oncol; 2016 Aug; 11(8):1242-1245. PubMed ID: 27343442
[TBL] [Abstract][Full Text] [Related]
11. Met/Hepatocyte growth factor receptor ubiquitination suppresses transformation and is required for Hrs phosphorylation.
Abella JV; Peschard P; Naujokas MA; Lin T; Saucier C; Urbé S; Park M
Mol Cell Biol; 2005 Nov; 25(21):9632-45. PubMed ID: 16227611
[TBL] [Abstract][Full Text] [Related]
12. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
Fujino T; Kobayashi Y; Suda K; Koga T; Nishino M; Ohara S; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
J Thorac Oncol; 2019 Oct; 14(10):1753-1765. PubMed ID: 31279006
[TBL] [Abstract][Full Text] [Related]
13. MET exon 14 skipping mutation positive non-small cell lung cancer: Response to systemic therapy.
Wong SK; Alex D; Bosdet I; Hughesman C; Karsan A; Yip S; Ho C
Lung Cancer; 2021 Apr; 154():142-145. PubMed ID: 33667719
[TBL] [Abstract][Full Text] [Related]
14. MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.
Miao YL; Xu QQ
Lung Cancer; 2019 Apr; 130():84-86. PubMed ID: 30885356
[TBL] [Abstract][Full Text] [Related]
15. DNA-Based versus RNA-Based Detection of MET Exon 14 Skipping Events in Lung Cancer.
Davies KD; Lomboy A; Lawrence CA; Yourshaw M; Bocsi GT; Camidge DR; Aisner DL
J Thorac Oncol; 2019 Apr; 14(4):737-741. PubMed ID: 30639620
[TBL] [Abstract][Full Text] [Related]
16. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
17. Deleterious c-Cbl Exon Skipping Contributes to Human Glioma.
Seong MW; Ka SH; Park JH; Park JH; Yoo HM; Yang SW; Park JM; Park D; Lee ST; Seol JH; Chung CH
Neoplasia; 2015 Jun; 17(6):518-24. PubMed ID: 26152360
[TBL] [Abstract][Full Text] [Related]
18. Novel MET exon 14 skipping analogs characterized in non-small cell lung cancer patients: A case study.
Shi M; Ma J; Feng M; Liang L; Chen H; Wang T; Xie Z
Cancer Genet; 2021 Aug; 256-257():62-67. PubMed ID: 33905998
[TBL] [Abstract][Full Text] [Related]
19. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation.
Peschard P; Ishiyama N; Lin T; Lipkowitz S; Park M
J Biol Chem; 2004 Jul; 279(28):29565-71. PubMed ID: 15123609
[TBL] [Abstract][Full Text] [Related]
20. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
Reungwetwattana T; Liang Y; Zhu V; Ou SI
Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
